Oral minoxidil use in androgenetic alopecia and telogen effluvium

Arch Dermatol Res. 2023 Mar;315(2):201-205. doi: 10.1007/s00403-022-02331-5. Epub 2022 Mar 4.


While current studies have supported oral minoxidil as a novel, adjunctive therapy in non-scarring forms of alopecia, there continues to be limited data on oral minoxidil for these conditions. To assess oral minoxidil use in the treatment of androgenetic alopecia and telogen effluvium, a multi-center, retrospective analysis was conducted in 105 adult patients treated for androgenetic alopecia and/or telogen effluvium with oral minoxidil (dose range 0.625-2.5 mg) once daily for ≥ 52 weeks, case matched by age (± 5 years) and gender with 105 controls with androgenetic alopecia and/or telogen effluvium who were not treated with oral minoxidil. 80 women (76.2%) with a mean age of 57.5 ± 13.56 (range 24-80) and 25 men (23.8%) with a mean age of 40.4 ± 13.79 (range 19-63) were included. Efficacy was evaluated based on provider assessment of clinical response and clinical photographic evaluation using a 3-point scale (worsening, stabilization, and improvement). 52.4% of patients demonstrated clinical improvement and 42.9% demonstrated stabilization. There was a significant difference in clinical response between the patient and control group, p < 0.001. Retrospective study design. These results suggest that oral minoxidil can be an effective treatment in androgenetic alopecia and telogen effluvium.

Keywords: Alopecia; Androgenetic alopecia; Hair loss; Telogen effluvium.

MeSH terms

  • Adult
  • Aged
  • Alopecia / drug therapy
  • Alopecia Areata* / drug therapy
  • Female
  • Humans
  • Male
  • Middle Aged
  • Minoxidil* / adverse effects
  • Retrospective Studies
  • Treatment Outcome


  • Minoxidil

Supplementary concepts

  • Diffuse alopecia